Furthermore, co-targeting PARP1 (with talazoparib) and CD24 (with anti-CD24 mAb) elicited synergistic antitumor effects in human pancreatic cancer animal models (Fig. 3C2) [66]. This evidence concerns the gene PARP1 and familial pancreatic carcinoma.